CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 80.96% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

BioNTech's Q3 revenue falls on lower COVID-19 vaccine demand

By Reuters News


Overview

  • Germany biopharma firm's Q3 revenue declined yr/yr on lower COVID-19 vaccine demand

  • Adjusted diluted EPS and net profit for Q3 fell from prior year

  • Company raised full-year 2026 revenue guidance midpoint, citing Q3 performance


Outlook

  • BioNTech raises full-year 2026 revenue guidance midpoint to €1.7–1.9 bln

  • Company maintains guidance for 2026 adjusted R&D expenses at €2.0–2.3 bln

  • Company maintains guidance for 2026 adjusted SG&A expenses at €700–800 mln


Result Drivers

  • COVID-19 VACCINE DEMAND - Co said expected lower market demand for COVID-19 vaccines drove revenue decline

  • ONCOLOGY INVESTMENT - Higher R&D expenses mainly due to increased spending on late-stage immuno-oncology and antibody-drug conjugate programs

  • PIPELINE PRIORITIZATION - Impairment and restructuring costs from pipeline prioritization affected operating results


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

EUR 1.29 bln

Q3 EPS

EUR 0.73

Q3 Net Income

EUR 184.50 mln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 15 "strong buy" or "buy", 8 "hold" and no "sell" or "strong sell"


Reuters Recommended Reads

  • Nov 2 - Switzerland's CRISPR Therapeutics Q3 CASGEVY revenue jumps 30% sequentially

  • Nov 2 - Ireland's Jazz Pharmaceuticals Q3 revenue beats; 2026 outlook lifted

  • Nov 3 - Lonza to buy five US sites from Merck KGaA


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.